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Cannabis and tolerance: acute 
drug impairment as a function of 
cannabis use history
J. G. Ramaekers1, J. H. van Wel1, D. B. Spronk2, S. W. Toennes3, K. P. C. Kuypers1, 
E. L. Theunissen1 & R. J. Verkes2,4
Cannabis use history as predictor of neurocognitive response to cannabis intoxication remains subject 
to scientific and policy debates. The present study assessed the influence of cannabis on neurocognition 
in cannabis users whose cannabis use history ranged from infrequent to daily use. Drug users (N = 122) 
received acute doses of cannabis (300 μg/kg THC), cocaine HCl (300 mg) and placebo. Cocaine served 
as active control for demonstrating neurocognitive test sensitivity. Executive function, impulse 
control, attention, psychomotor function and subjective intoxication were significantly worse after 
cannabis administration relative to placebo. Cocaine improved psychomotor function and attention, 
impaired impulse control and increased feelings of intoxication. Acute effects of cannabis and cocaine 
on neurocognitive performance were similar across cannabis users irrespective of their cannabis use 
history. Absence of tolerance implies that that frequent cannabis use and intoxication can be expected 
to interfere with neurocognitive performance in many daily environments such as school, work or traffic.
Cannabis is the most widely used illicit drug in the world1. Population data suggests that 4% of the global pop-
ulation uses cannabis and that one out of ten users develops daily use patterns2. The prevalence of cannabis 
use is expected to increase following recent legalization of medical and recreational use in several countries 
worldwide and the introduction of a legal cannabis industry. Recent findings of the 2014 Monitoring the Future 
Survey funded by the National Institute of Drug Abuse indicated that in US states that have legalized cannabis, 
40% of high school seniors had used cannabis compared with 26% in states that do not have legalized cannabis. 
Moreover, only 16.4% of high school seniors thought that cannabis smoking puts users at a greater risk3.
A solid volume of epidemiological and clinical research has established that cannabis use can produce adverse 
effects on cognitive function and mental health4 and increase risk of motor vehicle crashes5–7. Experimental, 
placebo controlled studies have repeatedly demonstrated that single doses of cannabis and THC cause a dose 
dependent reduction in performance as assessed with neurocognitive tasks measuring memory, attention, 
impulse control and motor function8–13. Performance impairments are maximal during the first hour after smok-
ing, decline over 2–4 hrs after cannabis use9 and are detectable at serum ∆ 9-tetrahydrocannabinol (THC ) con-
centrations as low as 2–5 ng/ml14.
The majority of experimental performance studies to date have been conducted in occasional users of can-
nabis with a low frequency of lifetime use. It has been suggested that performance impairment during cannabis 
intoxication is less in frequent cannabis users as a consequence of tolerance. Early studies of cannabis tolerance in 
humans suggest that prolonged administration of cannabis can reduce subjective15–17 and physiologic responses18 
to cannabis intoxication. It is less clear however whether repeated use of cannabis will also alter the neurocog-
nitive response because systematic studies are lacking. A few studies performed in small samples of heavy can-
nabis users (i.e. N = 12–24) indicated that cannabis produced minimal changes to cognitive and psychomotor 
function19–23. Other studies however indicated that heavy cannabis users remain very sensitive to the impairing 
effects of THC on impulse control20,24 or on a wider range of neurocognitive domains when assessed in a larger 
sample size25. Cannabis use history as predictor of neurocognitive response to cannabis intoxication therefore 
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remains subject to scientific discussion as well as policy debates regarding cannabis-law reforms. For example, 
the potential for tolerance development has been raised as a practical concern against imposing per se laws for 
driving under the influence of cannabis26.
The present study was designed to systematically assess the influence of cannabis on performance in a large 
sample of cannabis users whose cannabis use history ranged from infrequent to daily use. Executive function, 
impulse control, attention and psychomotor function were assessed by means of a neurocognitive test battery 
with demonstrated sensitivity to cannabis intoxication20,23. Cannabis users received single doses of placebo, can-
nabis and cocaine on separate occasions. Cocaine served as an additional active control for demonstrating test 
sensitivity to drug challenges. It was expected that acute impairment following cannabis administration would 
be identical across users in the absence of tolerance and decrease as a function of cannabis use history in the 
presence of tolerance.
Methods
Participants. Participants were recruited at 2 study sites (i.e. Maastricht and Nijmegen) that participated 
in this multicenter trial. In total, 132 users of cannabis and cocaine (male N = 96, female N = 26) entered the 
study. Ten participants dropped out for various non-study related reasons and a total of 122 subjects completed 
all treatments conditions. Mean age of participants was 22.8 (min-max: 18–39) yrs. Participants were recruited 
through advertisements in local newspapers, flyers distributed at college campuses, bars, night clubs, concerts, 
head shops and by word of mouth. Candidates received a medical examination by the medical supervisors who 
determined study eligibility. The medical supervisor checked vital signs, conducted a resting 12-lead electrocar-
diogram (ECG), took blood and urine samples. Participants filled out a standard questionnaire on medical as 
well as drug use history. Standard blood chemistry, hematology and drug screen tests were conducted on blood 
and urine samples respectively. Inclusion criteria were: written informed consent; age 18–40 yrs; (regular) use of 
cannabis (i.e. ≥ 2 times/past 3 mo); cocaine use at least 5 times in the previous year, good physical and mental 
health and normal weight (BMI 18–28). Exclusion criteria were: cocaine dependence according to DSM-IV cri-
teria; use of psychotropic medicinal drugs, presence or history of psychiatric or neurological disorder; pregnancy 
or lactating; cardiovascular abnormalities; excessive alcohol use (> 20 units/week) or smoking (> 15 cigarettes/
day), and hypertension.
On average, participants had been regular users of cannabis and cocaine for 7 yrs (min-max: 1–23) and 3.2 yrs 
(min-max: 0.5–6) respectively. They reported an average use of cannabis and cocaine on 44.8 and 3.7 occasions 
(i.e. a discreet event or period of subjective high caused by smoking one or more cigarettes) respectively during 
the previous 3 months. The frequency distribution of cannabis and cocaine use across study participants prior 
to study entrance is shown in Fig. 1. Frequency of cannabis use ranged between 2 and 100 occasions during 
3 months prior to study entrance and included regular but infrequent users as well as daily users of cannabis. 
Participants were about equally distributed over the full range of cannabis use and were allocated to 4 mutually 
excluding cannabis use history groups: i.e. use on 1–24 (N = 33); 25–49 (N = 41), 50–74 (N = 23) and 75–100 
(N = 25) occasions during the past 3 months. Frequency of cocaine use was relatively comparable across par-
ticipants (range 1–20 times in the past 3 months) and did not differ between cannabis use history groups and 
consequently was not taken into account as a separate independent factor. Participants also reported the use of 
other substances such as MDMA (88%), amphetamines (73%), mushrooms (61%), LSD (20%) and a range of 
miscellaneous drugs (60%) such as nitrous oxide, DMT and ketamine.
This study was part of a large trial on the association between drug use, performance and impulse control 
(Dutch Trial Register, trial number NTR2127). The study was approved by the Medical Ethics Committee of 
Maastricht University and conducted according to the code of ethics on human experimentation established by 
the declaration of Helsinki (1964) and its amendments. Written informed consent was obtained from all subjects.
Design, drug dose and administration. Participants entered a double-blind, placebo-controlled, 3-way 
crossover study. Treatments consisted of placebo, 300 μ g/kg THC and a single dose of 300 mg cocaine HCl. 
Cannabis was prepared from batches containing 11–12% THC, a standard potency for cannabis sold at Dutch 
pharmacies. Cannabis placebo was prepared from a herbal plant mixture (Knaster) that contained no CNS active 
(i.e. THC) ingredients. Cannabis doses were tailored to each individual subject to represent weight calibrated 
doses of 300 μ g/kg THC and administered using a Volcano vaporizer (Storz & Bickel GmbH & Co, Tuttlingen, 
Germany). Cannabis (placebo) was vaporized at a temperature of about 225 °C and the vapour was stored in a 
polythene bag equipped with a valved mouthpiece. Subjects were instructed to inhale deeply and hold their breath 
for 10 s after each inhalation. Within 2–3 min, the bag was to be fully emptied. Cocaine HCl and placebo were 
administered in an opaque white capsule. Treatments were administered using a double dummy technique to syn-
chronize time of maximal drug concentrations (Tmax) during performance testing. Cocaine or cocaine placebo 
capsules were administered at 75 min prior (T0) to assessment of performance, whereas cannabis or cannabis pla-
cebo was inhaled 15 min prior (T1) to performance testing. Treatment conditions were separated by a minimum 
wash-out period of 7 days. Treatment orders were counterbalanced across participants.
Procedures. Participants received training of tests and procedures on a separate day prior to the treatment 
conditions. Participants were instructed to refrain from drug use (except for cannabis) throughout the study. In 
the morning of test days, urine screens were used to check for the presence of benzodiazepines, opiates, cocaine, 
cannabis, MDMA and (meth)amphetamine. Subjects were also questioned about their last time of cannabis use 
upon arrival on test days. All subjects indicated that they did not smoke cannabis in the morning prior to testing. 
A breathalyzer was used to check for the presence of alcohol. Female participants underwent a pregnancy test. 
Participants were only allowed to proceed when test results for drug (except cannabis) and alcohol use and preg-
nancy were negative. Participants that passed the screen test received a standard breakfast, followed by baseline 
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measures of vital signs (blood pressure and heart rate) and a sample of blood (prior to T0). Drug and placebo 
were administered according to the double dummy procedure explained above. Vital signs, blood samples and 
performance tests were scheduled within 5 min following T1. Performance tests were completed within 1 hr fol-
lowing T1.
Neurocognitive performance. A neurocognitive test battery with demonstrated sensitivity to cannabis 
intoxication20,23,25 was employed to assess executive function, impulse control, attention and psychomotor func-
tion. The battery consisted of the tower of London (TOL), stop signal task (SST), critical tracking task (CTT), 
divided attention task (DAT) and a subjective evaluation of intoxication.
TOL is a decision-making task that measures executive function and planning27. It consists of 
computer-generated images of initial and target-arrangements of three colored balls on three sticks. The partici-
pant decides as quickly as possible, whether the end-arrangement can be accomplished in 2, 3, 4, or 5 steps from 
the initial arrangement by pushing the corresponding coded button. The total number of correct decisions is the 
main outcome measure.
SST measures motor impulsivity28, which is defined as the inability to inhibit an activated or pre-cued response 
leading to errors of commission. The task requires participants to make quick key responses to visual go signals 
(Go-trials), i.e. the letters ABCD presented one at a time in the middle of the screen, and to inhibit any response 
when a visual stop signal, i.e. “* ” in one of the four corners of the screen, is presented at predefined delays (No-go 
trials). The major dependent variable is the number of commission errors on stop trials.
CTT measures the ability to control a displayed error signal in a first-order compensatory tracking task29. Error 
is displayed as a horizontal deviation of a cursor from the midpoint on a horizontal, linear scale. Compensatory 
joystick movements null the error by returning the cursor to the midpoint. The frequency at which the participant 
Figure 1. Randomization of participants (A) and frequency distribution of cannabis and cocaine use 
across study participants (N = 122) prior to study entrance and number of participants allocated to  
4 cannabis use history groups (B).
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loses control is the critical frequency or lambda. The test includes five trials of which the lowest and the highest 
score are removed; the average of the remaining scores is taken as the final lambda-c (rad/sec) score.
DAT measures the ability to divide attention between two tasks performed simultaneously20. Participants 
were asked to perform the same tracking task as described above but now at a constant level of difficulty. As a 
secondary task, the participant was instructed to monitor 24 single digits (0 to 9) that were presented in the four 
corners of the computer screen (6 digits per corner). These numbers changed asynchronously every 5 seconds. 
The participants were instructed to react to the target number ‘2’ by removing their foot as fast as possible from a 
pedal switch and return. Average tracking error (mm), and percentage of correct responses (hits) to the target are 
the dependent performance measures.
Subjective intoxication was measured by means of a visual analogue scale (10 cm). Participants rated their 
level of ‘intoxication’, relative to their highest level of intoxication ever (0 = no intoxication, 10 = extremely 
intoxicated).
Pharmacokinetics. Serum was used for detection of cannabinoids whereas cocaine and metabolites were 
determined in sodium fluoride stabilized plasma. The determination of THC, 11-hydroxy-THC (THC-OH), 
11-nor-9-carboxy-THC (THC-COOH), cocaine (COC), benzoylecgonine (BZE) and ecgonine methyl ester 
(EME) in plasma was performed in a specialized forensic-toxicological laboratory using validated procedures30,31.
Statistics. A total of 122 participants completed all treatment conditions (see Fig. 1a). Data was missing in a 
varying number of participants for each neurocognitive task . Only participants with complete datasets entered 
the statistical analyses for subjective intoxication (N = 120), TOL (N = 113), SST (N = 114), CTT (N = 113) and 
DAT (N = 92). The association between performance during drug intoxication and cannabis use was analyzed 
according to the following steps. First, a GLM repeated measures ANOVA with Drug (3 levels) as within subject 
factor and Cannabis use history (4 levels) as between group factor was conducted to establish overall effects of 
both factors and their interaction. The GLM model subsequently established the effects of cannabis and cocaine 
and their interaction with cannabis use history separately by means of drug-placebo contrasts. Second, difference 
scores from placebo were calculated for all participants and in all drug conditions. Individual changes (from 
placebo) in performance during cannabis and cocaine were subsequently correlated (Pearson-r) to individual 
frequencies of cannabis use over the past 3 months.
Results
Neurocognitive performance. Mean (se) subjective intoxication and task performance following acute 
doses of cannabis, cocaine and placebo as a function of cannabis use history are shown in Fig. 2. GLM analyses 
revealed significant (p < 0.05) overall effects of the factor Drug on every neurocognitive measure and significant 
overall interactions between the factor Drug and Cannabis use history on CTT (lambda-c) and DAT (tracking 
error) measures. There was no main effect of the factor Cannabis use history. Subsequent contrasts revealed 
that cannabis induced feelings of intoxication and produced impairment on all performance measures. Cocaine 
also induced feelings of intoxication, improved performance on CTT and DAT and impaired performance on 
SST. CTT performance during cannabis and cocaine intoxication significantly varied as a function of cannabis 
use history, indicating that cocaine-induced stimulation increased and cannabis-induced impairment decreased 
with increasing frequency of cannabis use. All other measures did not reveal any interaction between cannabis or 
cocaine intoxication and cannabis use history. Subjective intoxication following cannabis administration tended 
(p = 0.07) to decrease with increasing frequency of cannabis use. A summary of GLM drug-placebo contrasts for 
all measures is provided in Table 1.
Correlational analyses between individual changes (from placebo) and individual cannabis use frequency con-
firmed GLM findings. Frequency of cannabis use correlated significantly with change in subjective intoxication 
following cannabis administration and with change in CTT performance following both cannabis and cocaine. 
A summary of (significant) correlations between individual performance changes during drug intoxication and 
cannabis use frequency is shown in Fig. 3.
Control measures. One-way ANOVA revealed that THC and cocaine concentrations after administration 
of cannabis and cocaine did not significantly differ between cannabis use history groups. Mean concentrations of 
THC, cocaine and their main metabolites averaged across all participants are given in Table 2.
Mean baseline THC concentrations prior to drug and placebo administration did differ between cannabis use 
history groups (F3,338 = 21,7; p = 0.000) and were highest in (near) daily users. Baseline THC concentrations were 
significantly correlated with frequency of cannabis use (r = 0.38) across treatment conditions: i.e. higher concen-
trations were associated with more frequent use. Baseline THC and cannabis use history correlated significantly 
with subjective intoxication, but not CTT performance, during placebo. Baseline THC did not correlate with per-
formance and subjective intoxication following cannabis and cocaine administration. A summary of significant 
correlations between baseline THC, cannabis use history, subjective intoxication and CTT performance in the 
placebo condition is shown in Fig. 4.
Discussion
The current study confirmed the presence of performance impairment across a wide range of neurocognitive 
domains during cannabis intoxication. Executive function, impulse control, attention and psychomotor function 
were significantly worse after cannabis administration as compared to placebo. These findings are in line with 
earlier studies demonstrating acute cannabis impairment in the same performance domains9,20,23,25. Likewise, 
cocaine effects on neurocognitive performance were also in the expected directions. The drug improved psycho-
motor function and attention but impaired impulse control. Similar findings have been reported before25 and are 
in line with the well characterized CNS stimulant properties of cocaine32.
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The present sample represented a diversity of cannabis users whose cannabis use history ranged from infre-
quent to daily use. Participants were about equally distributed over the full range of cannabis use which allowed 
for reliable assessment of acute drug effects in cannabis users with varying habits of use. In general, acute effects 
of cannabis and cocaine on neurocognitive performance were similar across cannabis users irrespective of their 
cannabis use history. Drug effects on executive function, impulse control and attention did not interact or corre-
late with cannabis use history. Two measures did indicate a significant contribution of cannabis use history to the 
neurocognitive response to drug intoxication. Frequency of cannabis use correlated significantly with change in 
subjective intoxication following cannabis administration and also correlated and interacted with (changes in) 
psychomotor performance (i.e. CTT) following both cannabis and cocaine. This suggests that subjective intox-
ication and psychomotor impairment following cannabis administration decrease with increasing frequency of 
cannabis use and that the stimulatory effect of cocaine on psychomotor function increases with increasing fre-
quency of cannabis use.
The current interactions between drug effects on subjective intoxication and psychomotor function and can-
nabis use history should however be interpreted with caution. Inspection of the data shows that these were mainly 
caused by performance fluctuations during placebo rather than during drug conditions. Psychomotor perfor-
mance during placebo declined with increased cannabis use while performance during cannabis and cocaine was 
Figure 2. Mean (se) subjective intoxication and task performance following acute doses of cannabis (CAN), 
cocaine (COC) and placebo (PLA) as a function of cannabis use history. 
CAN CAN × CUH COC COC × CUH
Subjective intoxication 0.000, F1,116 = 357,6 – 0.000, F1,116 = 75,6 –
TOL - correct decisions 0.000, F1,109 = 27,6 – – –
SST - commission errors 0.000, F1,110 = 15,5 – 0.000, F1,110 = 15,1 –
DAT - tracking error 0.019, F1,88 = 5,7 – 0.000, F1,88 = 55,7 –
DAT – hits 0.010, F1,88 = 6,9 – 0.000, F1,88 = 28,6 –
CTT - lambda-c 0.000, F1,109 = 13,9 0.032, F3,109 = 3.1 0.000, F1,109 = 39,7 0.008, F3,109 = 4.2
Table 1. Summary of significant changes (p, F) in subjective intoxication and performance measures 
induced by cannabis (CAN), cocaine (COC) and their interaction with Cannabis Use History (CUH) as 
indicated by GLM drug-placebo contrast analyses.
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relatively stable. Likewise, subjective intoxication ratings during placebo were slightly higher in frequent users as 
compared to infrequent cannabis users. Differences in subjective intoxication and psychomotor function between 
infrequent and frequent cannabis users during placebo may represent differences in baseline THC concentration 
across participants. Many participants were regular cannabis users who tested positive for THC prior to drug and 
placebo administration. Baseline THC levels indicate accumulated residuals from repeated use or recent use. The 
presence of low levels of THC in frequent users may have caused some degree of subjective high and performance 
impairment during placebo treatments.
Baseline THC levels were positively correlated to cannabis use history and generally higher in frequent canna-
bis users. Confounding between baseline THC and frequency of cannabis use was also evident from the finding 
that both factors were significantly correlated to subjective intoxication during placebo. Psychomotor perfor-
mance during placebo did not correlate with baseline THC and cannabis use history which is in line with previous 
studies showing that associations between THC concentrations and performance impairment are generally weak 
or absent6,14. Yet, baseline THC levels were high enough to expect intoxication and mild psychomotor impairment 
in some individuals14. Psychomotor function as measured by CTT has also been shown to be more sensitive to 
low levels of THC (i.e. between 2–5 ng/ml) as compared to other performance measures such as TOL and SST14, 
which may explain why cannabis use history interacted with (placebo) performance in some measures but not 
in others.
Overall, the present study demonstrates that cannabis induced impairment does not depend on cannabis 
use history and indicates that tolerance to impairing effects of cannabis on neurocognitive function is generally 
Figure 3. Scatterplots of individual changes (from placebo) in subjective intoxication and task 
performance following acute doses of cannabis (CAN) and cocaine (COC) as a function of cannabis use 
history. Significant (p < 0.05) correlations (r) between changes in subjective intoxication/task performance and 
cannabis use history are shown. ( Impairment  = − ; Improvement = + ).
THC [ng/ml]
THC-OH 
[ng/ml]
THC-COOH 
[ng/ml]
Cocaine 
[mg/L] BZE [mg/L]
EME 
[mg/L]
Baseline 1.57 (4.14) 0.62 (1.72) 20.91 (37.68) 0.00 (0.0) 0.00 (0.00) 0.00 (0.00)
Post drug 73.81 (63.09) 6.86 (4.32) 38.69 (33.38) 0.25 (0.19) 0.49 (0.27) 0.14 (0.11)
Table 2. Mean (sd) concentrations of THC, cocaine and their main metabolites at baseline and after drug 
administration (i.e. 5 min post smoking cannabis and 65 min post oral cocaine).
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absent in frequent users. These data confirm previous suspicions that neurocognitive impairments during can-
nabis intoxication do occur in infrequent as well as frequent cannabis users20,25,33,34. Previous studies reporting 
absence of neurocognitive impairment during cannabis intoxication in heavy, daily users employed small samples 
sizes19,20,23,35,36 or failed to measure and control for baseline THC19,21 which may have decreased study sensitivity. 
Alternatively, cannabis use frequency of participants is difficult to compare between studies but was estimated 
to be about twice as high in some studies19,21 as compared to those of (near) daily users in the present study. This 
suggests that tolerance to cannabis impairment may develop far beyond cannabis use frequencies reported in 
this paper. Still, the current study presents an integrative approach that employed a large sample ranging from 
infrequent to daily cannabis users to address the issue of cannabis intoxication and tolerance while controlling 
for THC concentration in blood. The present demonstration of absence of tolerance to cannabis impairment has 
important implications for risk perception in frequent users. It implies that neurocognitive function of daily or 
near daily cannabis users can be substantially impaired from repeated cannabis use, during and beyond the initial 
phase of intoxication. As a consequence, frequent cannabis use and intoxication can be expected to interfere with 
neurocognitive performance in many daily environments such as school, work or traffic.
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